![Sample our Physical Sciences journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/110819/TOC-Subject-Sample-2021-Physical-Sciences.jpg"})
Abstract
Meloxicam is used to treat pain or inflammation in treatment of rheumatoid arthritis, osteoarthritis, and other joint diseases. The main objective of this study is to develop a potential of nanoemulsion for transdermal delivery of meloxicam for the treatment of rheumatoid arthritis. Solubility of the meloxicam was determined in different oils, surfactants and cosurfactants. Of the oil tested, labrafil 1944 CS was chosen as oil phase of nanoemulsion, as it showed a good solubilizing capacity and excellent drug penetration. The nanoemulsion area was identified by constructing pseudo ternary phase diagram. The prepared nanoemulsion was subjected to different thermodynamic test. The nanoemulsion formulation was characterized for viscosity, particle size and polydispersity index (PCS), transmission electron microscopy (TEM), refractive index, in vitro permeation study and stability study. Drug content of all the formulations was found to be between 98.7±0.004% to 102.42±0.002%. The mean droplet size of C2 formulation was found to be small (60.6 nm) as compared to other formulation, polydispersity index 0.22, zeta potential 0.86 mv. The C2 formulation showed highest flux (29.69 μgcm-2h-1) as compared to other formulation. After stability study no significant change was observed in viscosity, drug content and pH. The result proposed that prepared nanoemulsion could be promising to improving transdermal efficacy of meloxicam in treatment of rheumatoid arthritis, osteoarthritis, and other joint diseases.